What is it? Why is it important?

The Risk Assessment Form (RAF) is a tool used by the SP-INV to document and assess risks that threaten the defined Critical to Quality (CtoQ) factors of a study. 

 

The RAF provides support on how to:

 

The assessment of study risks begins during study planning (e.g. study feasibility assessment, protocol development).

 

Risk assessment is a continuous process remaining active throughout study conduct until completion. Therefore, the RAF document is a living tool, regularly updated to address changing or emerging new risks.

What do I need to do?

As a SP-INV:

  • Implement a Quality by Design (QbyD) approach in your study, and define its CtoQ factors (i.e. aspects that stand out as being critical to the quality of your planned study)
  • Identify risks that threaten the integrity of the study`s CtoQ factors
  • Evaluate and prioritize risks, which will have an impact on the implementation of required risk control-measures. Note: risk control-measures should be fit for purpose and proportionate to the expected impact on CtoQ factors
  • Consult experts able to assist in risk assessment (e.g.  relevant comments and suggestions from Site-INV and study staff)
  • Ensure to document all information in the RAF, by keeping its content up to date and current

 

Implement a risk-based Quality Management System for the management of risks during study conduct.

 

Study risks may affect both time and resources needed to mitigate or prevent risk occurrence. These aspects must be considered when writing up the study budget.

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

References

ICH GCP E6(R3) – see in particular guideline

  • 2.3 Responsibilities
  • 3.10 Quality management

ICH E8(R1) – see in particular

  • 3.1 Quality by Design of clinical studies
  • 3.2 Critical to Quality Factors

ISO 31000 (access liable to costs) – see in particular section

  • Risk management: Principles and guidelines

Documents

 

Abbreviations
  • CtoQ – Critical to Quality
  • CTU – Clinical Trials Unit
  • ICH GCP – International Council for Harmonisation Good Clinical Practice
  • ISO - International Organization for Standardization
  • QbyD - Quality by Design
  • RAF – Risk Assessment Form
  • Site-INV – Site-Investigator
  • SOP – Standard Operating Procedures
  • SP-INV – Sponsor-Investigator
  • WI – Working Instruction
Basic ↦ Quality and Risk ↦ Risk-Based Approach to Quality ↦ Risk Assessment Form
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Basic ↦ Quality and Risk ↦ Risk-Based Approach to Quality ↦ Risk Assessment Form